PK and Safety of CKD-333 Low Dose in Healthy Volunteers

Phase 1, randomised, open-label trial of candesartan + amlodipine + atorvastatin in hypertension (HTN) and hyperlipidemia (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve from time zero to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Status: unknown.